Form 4 Filing for Acrivon Therapeutics, Inc.

This filing reports a transaction by Shacham Sharon, a director at Acrivon Therapeutics, Inc. On May 18, 2026, 9,366 restricted stock units (RSUs) were granted. These RSUs are set to vest in full on May 18, 2027, contingent upon Sharon's continued service. The reported value of these shares is $0, indicating they were likely granted as part of a compensation package rather than purchased. Following this transaction, Sharon holds 9,366 shares.